Open Label Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for a Single Adult With Non-Tuberculous Mycobacteria Infection

Trial Profile

Open Label Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for a Single Adult With Non-Tuberculous Mycobacteria Infection

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Mycobacterial infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Status changed from planning to recruiting.
    • 01 Nov 2017 New trial record
    • 31 Oct 2017 According to a Novoteris media release, the Therapeutic Products Directorate of Health Canada has cleared the clinical trial application for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top